2025 research hotspots and prospects of endocrine therapy for HR⁺/HER2^- breast cancer

Hormone receptor-positive(HR⁺)/human epidermal growth factor receptor 2-negative (HER2^-) breast cancer is the most common breast cancer subtype, with endocrine therapy as its core treatment modality. In recent years, the treatment paradigm has shifted toward a comprehensive man...

Description complète

Détails bibliographiques

Auteurs principaux:	张蓝心, 高子慧, 李宁, 韩佳鹏, 赵作伟, 李曼
Format:	Artigo
Langue:	Inglês
Publié:	Editorial Office of China Oncology 2026-02-01
Collection:	Zhongguo aizheng zazhi
Sujets:	Hormone receptor-positive Breast cancer CDK4/6 inhibitor Circulating tumor DNA <italic>ESR1 </italic>mutation <italic>PIK3CA </italic>mutation Oral SERD
Accès en ligne:	http://www.china-oncology.com/thesisDetails#10.19401/j.cnki.1007-3639.2026.02.005
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!